Requires prescriptions for certain patients to include patients' weight.
Note
The bill stipulates that the requirement will take effect 180 days after enactment, giving stakeholders time to adapt to the new regulations. This transitional period may allow for the development of best practices and clear guidelines on how to incorporate weight into prescription protocols effectively.
Impact
The bill is set to have a significant impact on medical practices and pharmacy operations in the state. With a formal requirement for weight to be included in prescriptions, healthcare providers will need to adapt their prescribing practices to comply with the new law. This change aims to better protect young patients, especially in emergency care settings where quick and accurate dosing can be critical. As a consequence, it may also necessitate additional training for medical staff regarding the importance of accurately measuring and documenting patient weight.
Summary
A4837 is a legislative bill introduced in New Jersey that mandates prescriptions for patients aged 18 years or younger to include the patient's weight in kilograms. This requirement aims to enhance the accuracy of medication dosing in pediatric patients, ensuring healthcare providers can prescribe medications more safely and effectively. By standardizing the inclusion of weight on prescriptions, the bill addresses concerns over pediatric dosing errors that could arise from weight miscalculations.
Contention
Although the impact of this bill is largely seen as beneficial for pediatric health and safety, there may be some contention regarding the implementation stages. Healthcare providers may express concerns about the practicality of consistently measuring and reporting patient weight on prescriptions, especially in busy clinical settings. Discussions may also arise around how to handle situations where a patient’s weight is unavailable or difficult to ascertain at the time of prescribing.
Allows remote patient monitoring of pregnant patients; requires reimbursement for remote patient monitoring rendered to certain Medicaid beneficiaries.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.